Cell processing is the series of laboratory steps used to collect, isolate, modify, multiply, and prepare human cells for use as a medical treatment. It sits at the heart of cell therapy, a growing branch of medicine where living cells, rather than traditional drugs, are used to treat diseases like cancer, autoimmune disorders, and degenerative conditions. The entire workflow is designed to turn a raw biological sample into a consistent, safe product that can be infused or transplanted into a patient.
Why Cell Processing Matters
Unlike a pill that can be synthesized identically millions of times, a cell therapy product is alive. Cells are sensitive to temperature, timing, contamination, and handling. The goal of cell processing is to control every variable so the final product works the same way every time, regardless of which patient’s cells were used or which technician did the work. A successful cell therapy is a consistent, safe, and effective cell product, and getting there requires identifying potential manufacturing problems early so they can be solved before a therapy reaches patients.
The Core Steps
Cell processing follows a general sequence, though the specifics change depending on the type of therapy being made.
- Collection: Cells are gathered from a donor or the patient themselves, often from blood, bone marrow, or tissue samples.
- Isolation: The target cells are separated from everything else in the sample. This might involve spinning the sample in a centrifuge or using magnetic beads that latch onto specific cell types.
- Modification (when needed): For some therapies, cells are genetically reprogrammed to give them new abilities, such as recognizing and attacking cancer cells.
- Expansion: The isolated cells are grown in controlled conditions to multiply them from a small starting number into the millions or billions needed for treatment.
- Purification and concentration: Unwanted byproducts, leftover growth media, and dead cells are removed, and the remaining healthy cells are concentrated into a smaller volume.
- Formulation and cryopreservation: The final product is mixed into a solution suitable for infusion and either used fresh or frozen for later use.
How CAR-T Therapy Illustrates the Process
CAR-T therapy is one of the most well-known examples of cell processing in action. It treats certain blood cancers by reprogramming a patient’s own immune cells to hunt down tumor cells. The process starts with leukapheresis, a procedure that filters white blood cells out of the patient’s blood. From that collection, specific immune cells called T cells are isolated and activated in the lab.
Next comes genetic modification. All currently approved CAR-T products use engineered viruses to deliver new genetic instructions into the T cells. These instructions tell the cells to build a receptor on their surface that recognizes a marker found on cancer cells. Newer methods that don’t rely on viruses are in development, including gene-editing tools and systems that temporarily insert instructions using small molecules of RNA, though these aren’t yet in approved products.
Once modified, the T cells are expanded in culture. Conventional manufacturing takes one to two weeks of growth. Newer abbreviated processes can compress this to 24 to 72 hours, and next-generation approaches aim to reach a finished product within a single day. Shorter timelines matter because critically ill patients often can’t afford to wait weeks for their treatment to be manufactured.
Autologous vs. Allogeneic Processing
A fundamental distinction in cell processing is whether the cells come from the patient (autologous) or from a separate donor (allogeneic). Each model creates very different manufacturing challenges.
Autologous processing means every batch is made for one specific patient. There’s virtually no risk of immune rejection, since the body recognizes its own cells. The downside is that each patient’s cells behave differently. Cells from someone with a serious illness may grow poorly or inconsistently, and the entire isolation-to-infusion cycle takes weeks.
Allogeneic processing uses cells from healthy donors, which can be manufactured in large batches and stored as an off-the-shelf product ready when a patient needs it. This simplifies logistics and allows donor selection for the healthiest, most productive cells. The tradeoff is a more complex biological challenge: the recipient’s immune system may attack the foreign cells, requiring additional engineering to reduce that risk.
Quality Standards and Release Testing
Before a processed cell product reaches a patient, it must pass a battery of quality checks. One of the most critical is cell viability, the percentage of cells in the final product that are alive and functional. For commercially manufactured CAR-T products, the release specification is typically at least 80% viability. Clinical trials have used a threshold as low as 70%, and outcomes data supports that as a reasonable minimum.
Other release criteria include confirming the cells are the correct type (purity), verifying that no bacteria or other contaminants are present (sterility), and checking that the genetic modification was successful when applicable. Every one of these tests must pass before the product is cleared for infusion.
The Regulatory Framework
In the United States, the FDA regulates cell-based products under a set of rules known as Current Good Tissue Practice, or CGTP. These rules cover every aspect of manufacturing: facility design, environmental controls, equipment maintenance, supply chain management, labeling, storage, and distribution. A core requirement is that every establishment involved in making cell products must maintain a quality program specifically designed to prevent the transmission of communicable diseases.
One notable rule: cells from two or more donors must never be pooled, meaning physically mixed in the same container, during manufacturing. This prevents cross-contamination and ensures traceability. When a cell product also qualifies as a drug or medical device, additional Good Manufacturing Practice regulations apply on top of the tissue practice rules.
Cleanroom Environments
Cell processing takes place in cleanrooms, highly controlled spaces where the air is continuously filtered to remove microscopic particles that could contaminate the product. Cleanrooms are rated by ISO class, with lower numbers meaning cleaner air. An ISO class 5 room, the standard for the most sensitive processing steps, allows no more than 3,520 particles (0.5 micrometers or larger) per cubic meter of air. For context, a typical office might have millions of such particles in the same volume.
Less critical steps, like equipment preparation, may take place in ISO class 7 or 8 environments. Staff working in these rooms wear gowns, gloves, masks, and shoe covers, and they follow strict protocols for entering and exiting to avoid introducing contaminants.
Automated Processing Platforms
Much of cell processing has historically been done by hand, with technicians performing each step in a biosafety cabinet. This works for small-scale clinical trials but doesn’t scale well. A single technician can only manage so many flasks, and every time a container is opened, there’s a contamination risk.
Automated closed systems are changing this. These platforms keep cells sealed inside sterile tubing and chambers throughout the entire process, from isolation through expansion to final harvest. One system uses a hollow-fiber bioreactor that provides a growth surface equivalent to 120 standard laboratory flasks in a single compact device. Another handles the complete workflow for stem cell processing: isolating cells from a bone marrow sample by density centrifugation, seeding them into culture, changing growth media on schedule, and harvesting the final product, all without a technician opening the system.
Other platforms use gentle rocking motion to keep cells suspended in nutrient-rich liquid, scaling from small research volumes up to 25 liters for clinical production. The shift toward automation reduces human error, improves batch-to-batch consistency, and makes it feasible to manufacture therapies for thousands of patients rather than dozens.
Cryopreservation and Storage
Many cell therapy products need to be frozen and stored until a patient is ready for treatment. Cryopreservation is a precise process. Cells are first incubated with a protective solution at around 4°C for 8 to 15 minutes. This solution prevents ice crystals from forming inside the cells, which would rupture and kill them.
The freezing itself happens in stages. An initial rapid cooling phase drops the temperature quickly, followed by a slower intermediate phase at about 1 to 5°C per minute, then a final cooling to somewhere between negative 80°C and negative 150°C. The exact rates and temperatures vary by cell type, but the principle is the same: cool slowly enough that water leaves the cell before it can freeze inside, but fast enough that the cell doesn’t shrink and collapse from dehydration. For long-term storage, products are typically held in liquid nitrogen at negative 196°C, where biological activity effectively stops and cells can remain viable for years.
Point-of-Care Processing
One of the most significant shifts in the field is the move toward point-of-care processing, where cells are manufactured at or near the patient’s bedside rather than shipped to a centralized facility. The U.S. government’s Advanced Research Projects Agency for Health (ARPA-H) has funded development of compact systems designed to process cells for therapy right in the hospital, using high-throughput blood processing technology adapted for cell modification.
Point-of-care manufacturing could dramatically reduce the time between cell collection and treatment, eliminate the risks and costs of shipping frozen products across the country, and ultimately make cell therapies accessible to hospitals that don’t have the infrastructure for a full-scale manufacturing cleanroom.